Indication: It has destructive and inhibitory effects on the morphology or proliferation of cell lines such as liver cancer, esophageal cancer, laryngeal cancer, lung cancer, and cervical cancer.

Indication: 1. Erlotinib alone is indicated for locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one chemotherapy regimen. 2. In two multicenter, randomized, placebo-controlled Phase III trials, the results showed that erlotinib combined with platinum-containing chemotherapy (carboplatin-paclitaxel; or gemcitabine-cisplatin) as first-line treatment for patients with locally advanced or metastatic NSCLC did not increase clinical benefit compared with platinum-containing chemotherapy alone, so it is not recommended for first-line treatment in the above situation. 3. Erlotinib alone can be used for maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer whose disease is stable after 4 cycles of platinum-based first-line chemotherapy. This indication is based on the results of a randomized, double-blind, placebo-controlled study (B018192) [see [Clinical Trials]]. No clinical research data comparing the use of erlotinib for treatment without progression and after progression after first-line chemotherapy have been obtained. 4. Clinical research on this product for first-line treatment of EGFR mutation populations is ongoing. It is recommended that the treating physician consider appropriate treatment options based on the research progress of this product and similar drugs and the patient's own condition.

Indication: 1. Erlotinib alone is indicated for locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one chemotherapy regimen. 2. In two multicenter, randomized, placebo-controlled Phase III trials, the results showed that erlotinib combined with platinum-containing chemotherapy (carboplatin-paclitaxel; or gemcitabine-cisplatin) as first-line treatment for patients with locally advanced or metastatic NSCLC did not increase clinical benefit compared with platinum-containing chemotherapy alone, so it is not recommended for first-line treatment in the above situation. 3. Erlotinib alone can be used for maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer whose disease is stable after 4 cycles of platinum-based first-line chemotherapy. This indication is based on the results of a randomized, double-blind, placebo-controlled study (B018192) [see [Clinical Trials]]. No clinical research data comparing the use of erlotinib for treatment without progression and after progression after first-line chemotherapy have been obtained. 4. Clinical research on this product for first-line treatment of EGFR mutation populations is ongoing. It is recommended that the treating physician consider appropriate treatment options based on the research progress of this product and similar drugs and the patient's own condition.

Indication: 1. Erlotinib alone is indicated for locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one chemotherapy regimen. 2. In two multicenter, randomized, placebo-controlled Phase III trials, the results showed that erlotinib combined with platinum-containing chemotherapy (carboplatin-paclitaxel; or gemcitabine-cisplatin) as first-line treatment for patients with locally advanced or metastatic NSCLC did not increase clinical benefit compared with platinum-containing chemotherapy alone, so it is not recommended for first-line treatment in the above situation. 3. Erlotinib alone can be used for maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer whose disease is stable after 4 cycles of platinum-based first-line chemotherapy. This indication is based on the results of a randomized, double-blind, placebo-controlled study (B018192) [see [Clinical Trials]]. No clinical research data comparing the use of erlotinib for treatment without progression and after progression after first-line chemotherapy have been obtained. 4. Clinical research on this product for first-line treatment of EGFR mutation populations is ongoing. It is recommended that the treating physician consider appropriate treatment options based on the research progress of this product and similar drugs and the patient's own condition.

Indication: 1. Erlotinib alone is indicated for locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one chemotherapy regimen. 2. In two multicenter, randomized, placebo-controlled Phase III trials, the results showed that erlotinib combined with platinum-containing chemotherapy (carboplatin-paclitaxel; or gemcitabine-cisplatin) as first-line treatment for patients with locally advanced or metastatic NSCLC did not increase clinical benefit compared with platinum-containing chemotherapy alone, so it is not recommended for first-line treatment in the above situation. 3. Erlotinib alone can be used for maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer whose disease is stable after 4 cycles of platinum-based first-line chemotherapy. This indication is based on the results of a randomized, double-blind, placebo-controlled study (B018192) [see [Clinical Trials]]. No clinical research data comparing the use of erlotinib for treatment without progression and after progression after first-line chemotherapy have been obtained. 4. Clinical research on this product for first-line treatment of EGFR mutation populations is ongoing. It is recommended that the treating physician consider appropriate treatment options based on the research progress of this product and similar drugs and the patient's own condition.

Indication: It is mainly used for patients with advanced ovarian cancer, testicular cancer, head and neck cancer, lung cancer, etc. who cannot tolerate vomiting caused by cisplatin treatment.

Indication: This product can be used for liver cancer, esophageal cancer, stomach and cardia cancer, lung cancer, and leukopenia. It can also be used as a preoperative medication for cancer or in combined chemotherapy.